ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Urinary Podocin mRNA as Predictor of Renal Allograft Function Decline

A. Naik1, J. Aqeel1, D. Cibrik2, M. Samaniego3, L. Wickman1, S. Wang1, M. Chowdhury1, R. Wiggins1

1University of Michigan, Ann Arbor, MI, 2University of Kansas, Kansas City, KS, 3Henry Ford, Detroit, MI

Meeting: 2019 American Transplant Congress

Abstract number: B41

Keywords: Biopsy, Glomerular filtration rate (GFR), Graft function, Proteinuria

Session Information

Session Name: Poster Session B: Biomarkers, Immune Monitoring and Outcomes

Session Type: Poster Session

Date: Sunday, June 2, 2019

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

*Purpose: Traditional biomarkers (such as proteinuria, 1year eGFR) as well as validated risk prediction tools such as the Birmingham Risk Score predict risk of ESRD. However, the ideal biomarker is one that is associated with smaller changes in allograft function such that early intervention is likely to be beneficial in retarding progression. In addition, biomarkers that are nephron segment specific will allow to delineate mechanistic processes driving allograft dysfunction.

*Methods: 125 consenting kidney transplant recipients had urines collected over the first year (2012-2015). Patients were followed till June 2017, graft failure or death whichever was earlier. Demographic and clinical data including eGFR was collected. Urines were analyzed for proteinuria as well as absolute mRNA quantification for podocin, nephrin (podocyte specific markers), Aquaporin2 (distal collecting tubule) and TGFbeta1 (measure of profibrotic activity). Absolute mRNA data was normalized to urine creatinine. Data on glomerulosclerosis (GS) and Interstitial Fibrosis Tubular Atrophy (IFTA) was obtained from 1year surveillance biopsies or last biopsy in the first year. Linear regressions were used to determine slope of eGFR decline for individual patient from time of first urine collection to end of follow-up. “Progressors” were defined as those in whom eGFR declined by >3 ml/min/year. K-fold cross validation techniques were used to split data into derivation and validation cohorts.

*Results: Overall 10,327 follow up eGFR observations and 547 urine samples were available for analysis. Twenty grafts were lost in follow up with 10 due to death. Table below highlights comparison of selected urine mRNA markers with traditionally used predictors clinical and histological predictors. Urine mRNA markers outperformed proteinuria, renal function and histological parameters in predicting risk of progression. Among urine mRNA markers only podocin and TGFbeta1 predicted risk of progression ( LCL of 95%CI was >0.5).

$$MISSING OR BAD TABLE SPECIFICATION {02519B34-3398-453A-A6F3-56160113E55F}$$

Comparison of Urine mRNA markers with traditional predictors of allograft function
Predictors ROC (Derivation Cohort) 95% CI ROC (Validation Cohort) 95% CI
UPodCR 0.70 0.57-0.83 0.70 0.56-0.83
UTGFbeta1 0.68 0.57-0.80 0.64 0.52-0.77
1yr avg. UPCR 0.63 0.48-0.77 0.59 0.45-0.73
1yr eGFR (4v MDRD) 0.54 0.39-0.69 0.25 0.14-0.36
GS% 0.43 0.29-0.57 0.37 0.22-0.52
Mild IFTA 0.54 0.41-0.67 0.46 0.31-0.61
Moderate to SevereIFTA 0.52 0.43-0.61 0.37 0.23-0.51

Other predictors that were tested and not significant: Rejection,CMV and BKV infections. Nephrin was excluded due to collinearity with podocin.

*Conclusions: The average first year urine podocin mRNA is a good biomarker for predicting allograft function decline (of >3 ml/min/year over a median 4.5years) compared to traditionally used biomarkers. Further internal and external validation studies as well as comparison with other mRNA markers are needed to establish clinical utility.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Naik A, Aqeel J, Cibrik D, Samaniego M, Wickman L, Wang S, Chowdhury M, Wiggins R. Urinary Podocin mRNA as Predictor of Renal Allograft Function Decline [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/urinary-podocin-mrna-as-predictor-of-renal-allograft-function-decline/. Accessed May 11, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences